Welcome to our dedicated page for ORGANON & CO SEC filings (Ticker: OGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Patent expirations, FDA safety updates, and global manufacturing data make Organon & Co鈥檚 disclosures dense. Finding how a contraceptive brand鈥檚 revenue shifted, or whether a biosimilar launch triggered new litigation, means combing through hundreds of pages. If you have ever asked, 鈥淗ow do I read Organon & Co SEC filings explained simply?鈥� this page is for you.
Stock Titan鈥檚 AI turns every Organon & Co annual report 10-K simplified, Organon & Co quarterly earnings report 10-Q filing, and Organon & Co 8-K material events explained into plain-English summaries. Need real-time alerts? We capture Organon & Co Form 4 insider transactions real-time the moment they hit EDGAR, spotlighting executive stock moves before market close. Our platform links each filing type to questions investors actually ask:
- 10-K / 10-Q 鈥� segment sales for women鈥檚 health, biosimilar revenue trends, and R&D pipeline costs, plus AI-driven Organon & Co earnings report filing analysis.
- 8-K 鈥� drug-approval milestones and manufacturing notices, with concise context so understanding Organon & Co SEC documents with AI takes minutes, not hours.
- Form 4 鈥� monitor Organon & Co insider trading Form 4 transactions and flag unusual buying in advance of biosimilar launches.
- DEF 14A 鈥� review the Organon & Co proxy statement executive compensation for insight into incentive alignment.
Whether you鈥檙e tracking patent-cliff risk or confirming Organon & Co executive stock transactions Form 4, our expert analysis and AI-powered summaries let you focus on decisions, not document mining. All filings, all in one place鈥攗pdated as soon as Organon presses 鈥渟ubmit.鈥�
Organon & Co. insider filing (Form 4) reports that Juan Camilo Arjona Ferreira, Head of R&D & CMO and an officer of Organon (OGN), had 11,519 restricted stock units vest on August 11, 2025. Those vested units were recorded as acquisitions of common stock at $0 per share. The filing also shows a disposition of 4,122 shares sold at $9.22 per share on the same date.
The form reports beneficial ownership figures after the transactions: 28,899.355 shares reported after the RSU acquisition line and 24,777.355 shares reported after the sale line. The Form 4 was signed by an attorney-in-fact on August 12, 2025. The filing notes that each RSU equals one share and that a final vesting installment is scheduled for August 11, 2026.
Organon & Co. (OGN) Q2 2025 condensed summary: Revenues were $1.594 billion for the quarter and $3.107 billion for the six months, versus $1.607 billion and $3.229 billion in the prior-year periods. Net income fell to $145 million in Q2 2025 (Q2 2024: $195 million) and $232 million year-to-date (YTD 2025) versus $396 million YTD 2024. Diluted EPS was $0.56 for the quarter and $0.89 YTD versus $0.75 and $1.53 in the prior-year periods.
Key cash and balance sheet items: cash and equivalents declined to $599 million at June 30, 2025 from $675 million at Dec 31, 2024; total assets $13.5 billion; total long-term debt (net of current portion) $8.781 billion; weighted-average interest rate on borrowings 5.0% and average maturity ~5.1 years. Operating cash flow provided $295 million YTD; investing used $210 million, including Dermavant consideration.
Material corporate actions disclosed: Dermavant acquisition (aggregate consideration $581 million; contingent consideration fair value $383 million; $75 million regulatory milestone paid in Q1 2025); March 2025 U.S. rights for Tofidence from Biogen (intangible $51 million recognized; upfront paid in July 2025); July 2025 acquisition of Oss Biotech site (aggregate $25 million, $15 million paid). The Company repurchased $242 million of 5.125% 2031 notes in Q2, recording a $42 million pre-tax gain. The Company implemented restructuring reducing headcount ~6% and recorded $88 million of restructuring costs YTD. Effective tax rates increased (Q2 2025: 37.0% vs Q2 2024: 17.3%).
FAQ
What is the current stock price of ORGANON & CO (OGN)?
What is the market cap of ORGANON & CO (OGN)?
